Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2633813 | 0.98 | HRH3 (0.42) | HRH3HPGDEPHX1MAPK1BTK | |
| SCHEMBL20918704 | 0.95 | HRH3 (0.42) | HRH3HPGDEPHX1MAPK1BTK | |
| SCHEMBL12002951 | 0.91 | HRH3 (0.44) | HRH3HPGDEPHX1MAPK1BTK | |
| SCHEMBL26132791 | 0.88 | HRH3 (0.37) | HRH3HPGDEPHX1MAPK1BTK | |
| SCHEMBL30415219 | 0.84 | HRH3 (0.39) | HRH3HPGDMAPK1BTK | |
| SCHEMBL25277997 | 0.84 | HRH3 (0.37) | HRH3HPGDEPHX1MAPK1BTK | |
| SCHEMBL4649839 | 0.83 | HRH3 (0.36) | HRH3HPGDEPHX1MAPK1BTK | |
| SCHEMBL30733879 | 0.81 | HPGD (0.35) | HRH3HPGDEPHX1BTKGPR119 | |
| SCHEMBL30718246 | 0.81 | HRH3 (0.36) | HRH3HPGDEPHX1MAPK1BTK | |
| SCHEMBL30686990 | 0.81 | HRH3 (0.40) | HRH3HPGDMAPK1BTKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660491-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | claimed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | claimed |
| WO-2023025159-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海领泰生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
| WO-2013170191-A1 | METHODS OF USING ANTAGONISTS OF NAD BIOSYNTHESIS FROM NICOTINAMIDE | GENENTECH, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| EP-2513066-A1 | SPHINGOSINE KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011082732-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
| US-20060135774-A1 | Method for producing pigment transparent preparations based on perylene-3,4,9,10-tetracarboxylic acid diimine | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2006-06-22 | — | — | US | disclosed |
| EP-1660491-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135774-A1 | Method for producing pigment transparent preparations based on perylene-3,4,9,10-tetracarboxylic acid diimine | RDX, USP9X, DDX1 | HRH3 665/4885HPGD 3175/4885EPHX1 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.